Results 121 to 130 of about 169,346 (179)
Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. [PDF]
World J Hepatol, 2018 Saberi B +5 more
europepmc +1 more source
Effectiveness of tnf inhibitors therapy in children with juvenile idiopathic arthritis aged 2 to 5 years [PDF]
Pediatr Rheumatol Online J, 2014 Opoka-Winiarska V +4 more
europepmc +1 more source
Coexistence of rheumatoid arthritis and ankylosing spondylitis. [PDF]
Reumatologia, 2015 Barczyńska TA +6 more
europepmc +1 more source
The Role of Programmed Types of Cell Death in Pathogenesis of Heart Failure with Preserved Ejection Fraction. [PDF]
Int J Mol SciJankowski J +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Revista Paulista de Reumatologia, 2021
O fator de necrose tumoral (TNF), descrito inicialmente na década de 1970, é um dos alvos de atuação molecular que mais atraiu a atenção nas últimas décadas. Durante a década de 1980, foi demonstrado o papel do TNF na etiopatogenia das doenças inflamatórias e estudos iniciais demonstraram uma concentração elevada dessa citocina no líquido sinovial e no
openaire +2 more sources
O fator de necrose tumoral (TNF), descrito inicialmente na década de 1970, é um dos alvos de atuação molecular que mais atraiu a atenção nas últimas décadas. Durante a década de 1980, foi demonstrado o papel do TNF na etiopatogenia das doenças inflamatórias e estudos iniciais demonstraram uma concentração elevada dessa citocina no líquido sinovial e no
openaire +2 more sources
Best Practice & Research Clinical Rheumatology, 2011
There are now five anti-tumour necrosis factor (TNF) drugs licenced for use in rheumatoid arthritis. This chapter examines the similarities and differences between the drugs and looks for clues with regard to their rational prescribing. The major difference is between the monoclonal antibody-based drugs and the soluble receptor etanercept.
Thalayasingam N, Isaacs JD
openaire +3 more sources
There are now five anti-tumour necrosis factor (TNF) drugs licenced for use in rheumatoid arthritis. This chapter examines the similarities and differences between the drugs and looks for clues with regard to their rational prescribing. The major difference is between the monoclonal antibody-based drugs and the soluble receptor etanercept.
Thalayasingam N, Isaacs JD
openaire +3 more sources
Annals of the New York Academy of Sciences, 2006
Abstract: Whenever serum estrogen concentrations are normal in rheumatoid arthritis (RA) patients, lower androgen concentrations (i.e., testosterone, androstenedione, and dehydroepiandrosterone sulfate [DHEAS]) are detected in the serum as well as in the synovial fluid of male and female RA patients.
CUTOLO, MAURIZIO +9 more
openaire +3 more sources
Abstract: Whenever serum estrogen concentrations are normal in rheumatoid arthritis (RA) patients, lower androgen concentrations (i.e., testosterone, androstenedione, and dehydroepiandrosterone sulfate [DHEAS]) are detected in the serum as well as in the synovial fluid of male and female RA patients.
CUTOLO, MAURIZIO +9 more
openaire +3 more sources
Rheumatoid Arthritis — Anti-TNF
International Immunopharmacology, 2015This review will focus on the recent information and strategies now informing best use of TNF inhibitor therapy in RA. These issues include the role of TNFi therapy in early RA management, anti-drug antibodies in TNFi therapy, updates on safety and optimal dosage regimens in long term management.
Khaldoun, Chaabo, Bruce, Kirkham
openaire +2 more sources